Gut bacterial enzyme keeps inflammation awayAn antimicrobial molecule produced by the human microbiota gut may help fight drug-resistant infections. more ➔
Tacalyx GmbH raises €7m in seed fundingGerman Tacalyx GmbH has baged €7m in seed financing to generate antibodies that home in on tumour-antigene specific carbohydrates (TACAs) of glycans. more ➔
Evotec and Takeda enter drug discovery dealEvotec SE and Takeda Pharmaceutical Company Ltd have entered a strategic drug discovery collaboration potentially worth $850m. Under the agreement, Evotec will develop at least five small molecule discovery … more ➔
EMA greenlights new medicinesAt its September meeting, the EMA’s CHMP recommended three innovative medicines for EU market approval. more ➔
New malaria lead kills 99.9% of pathogensDutch and US researchers have re-engineered non-druggable compounds that block the transmission and metabolism of the malaria parasite Plasmodium falciparum. more ➔
Versantis raises CHF16m in Series B financingSwiss Versantis AG has raised money in order to advance its liver detoxifying candidate VS-01 from ongoing Phase Ia trials to initial Phase IIa efficacy proof. more ➔
Lundback swallows migraine drug maker AlderDanish Lundbeck AS is has secured a stake in the migraine market by paying US$1.95bn (€1.76bn) to acquire Alder BioPharmaceuticals Inc. more ➔
PFF Group NV acquires stake in Autolus TherapeuticsPrague-based PPF Group has acquired a 19.2% stake in Autolus Therapeutics plc, a developer of T cell cancer therapies. more ➔
Researchers identify CTLA-4 response markerGerman and US researchers have found a biomarker that identifies tumours responding to CTLA-4 checkpoint blockers. more ➔
Inotrem SA raises €39m to provide POC for nangibotideFrench biotech Inotrem SA raised €39m to finance Phase IIb efficacy testing of its TREM1 blocker nangibotide (Motrem) in patients with septic shock. more ➔
